Adolescent obesity: Identifying a new group of at-risk youth

Pediatric Annals

Volumn 31, Issue 9, 2002, Pages 559-564

  Trent, Maria ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; HERBACEOUS AGENT; METFORMIN; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADOLESCENT DISEASE; BARIATRIC SURGERY; BODY FAT; BODY MASS; CLINICAL PRACTICE; COMORBIDITY; CONSTIPATION; ENDOCRINE DISEASE; ENVIRONMENTAL FACTOR; GENETIC DISORDER; HIGH RISK POPULATION; HUMAN; INSOMNIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; OVARY POLYCYSTIC DISEASE; PHYSICAL ACTIVITY; PSYCHOSOCIAL DISORDER; REVIEW; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0036745286     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-20020901-08     Document Type: Review

References (25)

1. Trojan RP, Flegal KM. Overweight children and adolescents: description, epidemiology, and demographics. Pediatrics. 1998;101:S497-S504.
2. Wang G, Deitz WH. Economic burden of obesity in youths aged 6-17 years: 1979-1999. Pediatrics. 2002;109(5):e81.
3. Pietrobelli A, Faith MS, Allison DB, et al. Body mass index as a measure of adiposity among children and adolescents: a validation study. J Pediatr. 1998;132:204-210.
4. Himes JH. Agreement among anthropometric indicators identifying the fattest adolescents. Intl J Obes. 1999;23:S18-21.
5. American Diabetes Association. Type 2 Diabetes in Children and Adolescents-Consensus Statement. Diabetes Care. 2000;23(12):381-389.
6. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346:802-810.
7. Kim C, McHugh C, Kwok Y, Smith A. Type 2 diabetes in Navajo adolescents. Western J Med. 1999;170:210-213.
8. Trent M, Rich M, Austin SB, Gordon CM. Quality of life in adolescents with polycystic ovary syndrome. Arch of Ped Adol Med. 2002;156:1-5.
9. Palmert MR, Gordon CM, Kartashov AI, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:1017-23.
10. Facchini FS, Hua N, Fahim A, Reaven GM. Insulin resistance as a predictor of age related diseases. J. Clin Endocrinol Metab. 2001;86:3574-3578.
11. Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA. 2001;286:2421-2426.
12. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. 2002;22(12):381.
13. Staffieri JR. A study of social stereotype of body image in children. J Perspect Soc Psychol. 1967;7:101-104.
14. Richardson AS, Goodman N, Hastorf AH, et al. Cultural uniformity in reaction to physical disabilities. Am Soc Rev. 1961;26:241-247.
15. Strauss RS. Childhood obesity and self-esteem. Pediatrics. 2000;105(1):e15.
16. Gortmaker SL, Must A, Perrin JM, et al. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med. 1993;329:1008-1012.
17. Deitz WH. Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics. 1998;101:S518-S525.
18. DeLiva A. What are the benefits of moderate weight loss? Exp Clin Endocrinol Diabetes. 1998;106:S10-S13.
19. Goetz DR, Caron W. A biopsychosocial model for youth obesity: consideration of an ecosystemic collaboration. Intl J Obes. 1999;23:S58-S64.
20. Risser WL, Gefter LR, Barratt MS, et al. Weight change in adolescents who used hormonal contraception. J Adolesc Health. 1999;24:433-436.
21. Ebbeling CB, Ludwig, DS. Treating obesity in youth: should dietary glycemic load be a consideration. Adv Pediatr. 2001;48:179-212.
22. Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized controlled trial of sibutramine. Obes Res. 1996;4:263-270.
23. Davidson M, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for two years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-242.
24. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
25. Silber T, Randolph J, Robbins S. Long-term morbidity and mortality in morbidly obese adolescents after jejunal ileal bypass. J Pediatr. 1986;108:3318-3322.